Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Front Immunol ; 5: 292, 2014.
Article in English | MEDLINE | ID: mdl-24982661

ABSTRACT

B-cell chronic lymphocytic leukemia (CLL) is the most frequent adult leukemia in the Western world. It is a heterogeneous disease characterized by clonal proliferation and the accumulation of CD5(+) mature B lymphocytes. However, the normal counterpart from which the latter cells arise has not yet been identified. CD27 expression and gene expression profiling data suggest that CLL cells are related to memory B-cells. In vitro, memory B-cells differentiate into plasma cells when stimulated with CpG oligodeoxynucleotide (CpG). The objective of the present study was therefore to investigate the ability of CpG, in the context of CD40 ligation, to induce the differentiation of CLL B-cells into antibody-secreting cells (ASCs). CD20(+)CD38(-) CLL B-cells were stimulated with a combination of CpG, CD40 ligand and cytokines (CpG/CD40L/c) in a two-step, 7-day culture system. We found that the CpG/CD40L/c culture system prompted CLL B-cells to differentiate into CD19(+)CD20(+)CD27(+)CD38(-)ASCs. These cells secreted large amounts of IgM and had the same shape as plasma cells. However, only IgMs secreted by ASCs that had differentiated from unmutated CLL B-cells were poly/autoreactive. Class-switch recombination (CSR) to IgG and IgA was detected in cells expressing the activation-induced cytidine deaminase gene (AICDA). Although these ASCs expressed high levels of the transcription factors PRDM1 (BLIMP1), IRF4, and XBP1s, they did not downregulate expression of PAX5. Our results suggest that CLL B-cells can differentiate into ASCs, undergo CSR and produce poly/autoreactive antibodies. Furthermore, our findings may be relevant for (i) identifying the normal counterpart of CLL B-cells and (ii) developing novel treatment strategies in CLL.

2.
Immunol Cell Biol ; 92(7): 591-604, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24797583

ABSTRACT

In this study, we investigated the capacity of chronic lymphocytic leukemia (CLL) B cells to undergo terminal differentiation into Ig-secreting plasma cells in T cell-independent and T cell-dependent responses. We used a two-step model involving stimulation with phorbol myristate acetate (PMA) and CD40L, together with cytokines (PMA/c and CD40L/c), for 7 days. We describe immunophenotypic modifications, changes in the levels of mRNA and protein for transcription factors and morphological and functional events occurring during the differentiation of CLL B cells into antibody-secreting cells (ASCs). The induction of differentiation differed significantly between the CD40L/c and PMA/c culture systems. The PMA/c culture system allowed CLL B cells to differentiate into IgM-secreting cells with an immunophenotype and molecular profile resembling those of preplasmablasts. By contrast, CD40L/c-stimulated cells had a phenotype and morphology similar to those of activated B cells and resembling those of the CLL B cells residing in the lymph node and bone marrow. These data suggest that the CLL B cells are not frozen permanently at a stage of differentiation and are able to differentiate into ASCs as appropriate stimulation are provided. The data presented here raise questions about the molecular processes and stimulation required for CLL B-cell differentiation and about the inability of CD40 ligand to induce differentiation of the CLL B cells.


Subject(s)
Antibody Formation/immunology , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , CD40 Ligand/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/metabolism , Tetradecanoylphorbol Acetate/immunology , Aged , Aged, 80 and over , Antigens, Surface/metabolism , B-Lymphocytes/pathology , Cell Differentiation , Cytokines/metabolism , Female , Gene Expression Regulation, Neoplastic , Humans , Immunoglobulin M/biosynthesis , Immunophenotyping , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Male , Middle Aged , Phenotype , Transcription, Genetic
3.
PLoS One ; 8(12): e82918, 2013.
Article in English | MEDLINE | ID: mdl-24376606

ABSTRACT

Although hepatocellular carcinoma (HCC) is one of the most common malignancies and constitutes the third leading cause of cancer-related deaths, the underlying molecular mechanisms are not fully understood. In the present study, we demonstrate for the first time that hepatocytes express signalling lymphocytic activation molecule family member 3 (SLAMF3/CD229) but not other SLAMF members. We provide evidence to show that SLAMF3 is involved in the control of hepatocyte proliferation and in hepatocellular carcinogenesis. SLAMF3 expression is significantly lower in primary human HCC samples and HCC cell lines than in human healthy primary hepatocytes. In HCC cell lines, the restoration of high levels of SLAMF3 expression inhibited cell proliferation and migration and enhanced apoptosis. Furthermore, SLAMF3 expression was associated with inhibition of HCC xenograft progression in the nude mouse model. The restoration of SLAMF3 expression levels also decreased the phosphorylation of MAPK ERK1/2, JNK and mTOR. In samples from resected HCC patients, SLAMF3 expression levels were significantly lower in tumorous tissues than in peritumoral tissues. Our results identify SLAMF3 as a specific marker of normal hepatocytes and provide evidence for its potential role in the control of proliferation of HCC cells.


Subject(s)
Antigens, CD/genetics , Carcinoma, Hepatocellular/genetics , Gene Expression Regulation, Neoplastic , Liver Neoplasms/genetics , Animals , Antigens, CD/metabolism , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor , Disease Progression , Humans , Injections, Subcutaneous , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , MAP Kinase Kinase 4/genetics , MAP Kinase Kinase 4/metabolism , Male , Mice , Mice, Nude , Mitogen-Activated Protein Kinase 1/genetics , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/genetics , Mitogen-Activated Protein Kinase 3/metabolism , Neoplasm Transplantation , Signal Transduction , Signaling Lymphocytic Activation Molecule Family , TOR Serine-Threonine Kinases/genetics , TOR Serine-Threonine Kinases/metabolism
4.
Ann Hematol ; 85(12): 833-40, 2006 Dec.
Article in English | MEDLINE | ID: mdl-16871390

ABSTRACT

Marked polyclonal immunoglobulin (Ig)G4 hypergammaglobulinemia has exceptionally been reported. Here we report on two Algerian patients who presented a syndrome characterized by anemia, plasmacytic lymphadenopathy, renal manifestations, and a marked polyclonal IgG4 hypergammaglobulinemia leading to a hyperviscosity syndrome in one case. The IgG4-expressing cell percentage was significantly increased in the peripheral blood lymphocytes collected from the two patients upon diagnosis. Moreover, in contrast with normal sera, both patients' sera significantly increased the percentage of IgG4-expressing cells when incubated with CD40-stimulated normal B lymphocytes. Similar effects were obtained with the culture supernatants of the patients' activated T cells. Anti-interleukin (IL) 4 and/or anti-IL-13 antibodies were unable to antagonize the IgG4 production. IL-4 and IL-13 serum concentrations were found to be normal in the two patients. The increased IgG4 production was found to be mediated by soluble factor(s), most probably secreted by activated T cells, which did not require the signal transducer and activator of transcription 6 signaling pathway.


Subject(s)
Anemia/complications , Hypergammaglobulinemia/complications , Immunoglobulin G/blood , Kidney Diseases/complications , Lymphatic Diseases/complications , Adolescent , Cells, Cultured , Culture Media, Conditioned/pharmacology , Female , Gene Expression/drug effects , Humans , Immunoglobulin G/metabolism , Kidney Diseases/blood , Lymphocyte Activation , Lymphocytes/metabolism , Male , Middle Aged , Plasma Cells/pathology , STAT6 Transcription Factor/blood , STAT6 Transcription Factor/metabolism
5.
Eur J Intern Med ; 15(7): 451-459, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15581750

ABSTRACT

BACKGROUND: Antineutrophil cytoplasmic antibodies (ANCA) can be associated with various disorders. However, their association with neutropenia has never been reported. METHODS: Nine patients with chronic unexplained neutropenia and ANCA were studied. Clinical charts were extensively analyzed and all patients underwent hematological and immunological investigations. RESULTS: All patients (6 women and 3 men) were Caucasian and had a mean age of 49 years (range 16-67 years). All presented with a neutropenia below 1.5x10(9)/L for more than 6 months. The neutropenia was <0.5x10(9)/L in six cases and moderate in three. There was no evidence of toxic- or drug-related neutropenia or of a hematological malignancy. Autoimmune anemia and/or thrombocytopenia were present in five patients. ANCA, with various specificities, were present in all patients. ANCA were associated with various other autoantibodies in eight patients, including antisurface-neutrophil antibodies in three cases. Four of the six patients with severe neutropenia experienced infections. Five patients were treated with hematopoietic growth factors, steroids, intravenous immunoglobulins, splenectomy, methotrexate and/or cyclophosphamide, allowing the neutrophil count to be restored transiently or permanently. CONCLUSIONS: A subset of patients with neutropenia of possible autoimmune origin may develop ANCA. Their detection would provide strong evidence of an autoimmune mechanism. Neutropenia should be added to the list of ANCA-associated diseases.

6.
Am J Hematol ; 77(3): 241-9, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15495255

ABSTRACT

A subset of anti-nuclear autoantibodies (ANA) are directed against nuclear envelope (NE) polypeptides and display by indirect immunofluorescence (IIF) a ring-like fluorescent pattern. We report herein 19 patients with autoimmune cytopenias associated with antibodies (Abs) to NE polypeptides. Anti-NE specificity was determined by immunoblot, using NE preparations and purified lamina fractions. Eleven sera reacted with lamin B(1), and two reacted with both lamin B(1) and an unidentified 150-kDa protein (p150). One serum reacted with only p150. Four sera reacted with lamins A and C, and one reacted with and an unidentified 52-kDa NE polypeptide (p52). Autoimmune cytopenias included hemolytic anemia (7 cases), thrombocytopenia (13 cases), and neutropenia (6 cases). Five patients had 2 (3 cases) or 3 (2 cases) different cytopenias. Antiphospholipid antibodies (APLA) were detected in 14 patients, 2 of whom experienced thromboembolic events. A liver disorder was present in 7 patients. Systemic lupus erythematosus and lupus-like syndrome were diagnosed in 11 and 2 patients, respectively. Cytopenias responded to steroids alone (13 patients), or together with intravenous immunoglobulins (2 patients), or cyclophosphamide (2 patients). Two patients did not require treatment. Our results suggest that anti-NE Abs need to be sought for in patients with peripheral cytopenias, particularly when they are associated with APLA and/or liver disorders. Their detection strongly suggests an autoimmune process. Such cytopenias are often manifestations of a lupus or lupus-like disease and are responsive to steroids.


Subject(s)
Autoantibodies/immunology , Autoimmune Diseases/immunology , Nuclear Envelope/immunology , Nuclear Proteins/immunology , Pancytopenia/immunology , Adolescent , Adult , Aged , Anemia, Hemolytic, Autoimmune/complications , Anemia, Hemolytic, Autoimmune/drug therapy , Anemia, Hemolytic, Autoimmune/immunology , Anemia, Hemolytic, Autoimmune/pathology , Autoimmune Diseases/complications , Autoimmune Diseases/drug therapy , Autoimmune Diseases/pathology , Coombs Test , Female , Follow-Up Studies , Humans , Immunoblotting , Liver Diseases/complications , Liver Diseases/pathology , Male , Middle Aged , Neutropenia/complications , Neutropenia/drug therapy , Neutropenia/immunology , Neutropenia/pathology , Pancytopenia/complications , Pancytopenia/drug therapy , Pancytopenia/pathology , Peptides/immunology , Purpura, Thrombocytopenic/complications , Purpura, Thrombocytopenic/drug therapy , Purpura, Thrombocytopenic/immunology , Purpura, Thrombocytopenic/pathology , Retrospective Studies , Treatment Outcome , Vasculitis/complications , Vasculitis/pathology
7.
FEBS Lett ; 563(1-3): 103-7, 2004 Apr 09.
Article in English | MEDLINE | ID: mdl-15063731

ABSTRACT

Cell shape was found to be a strong indicator of whether individual cells grow or die, and may play an important role in controlling apoptosis as well as cell growth. We compared here the behaviour of rounded Swiss 3T3 cells aggregated on a cellulose cuprophan membrane to those cultured on dish polystyrene. We demonstrated that cells aggregated on cellulose substrates for up to 48 h underwent programmed cell death that was associated with phosphatidylserine flipping and caspase 9 and caspase 3 activation, suggesting a mitochondria-dependent apoptotic process. In addition, we found that this phenomenon cannot be entirely explained by disengagement of alpha 5 beta 1 integrin ligation.


Subject(s)
Apoptosis , Cellulose/analogs & derivatives , Cellulose/metabolism , Fibroblasts/metabolism , Mitochondria/metabolism , Signal Transduction , Animals , Biocompatible Materials , Caspases/metabolism , Cell Adhesion , Cell Aggregation , Cell Size , Enzyme Activation , Fibroblasts/cytology , Mice , Polystyrenes/metabolism , Substrate Specificity , Swiss 3T3 Cells
8.
Oncogene ; 23(17): 3040-7, 2004 Apr 15.
Article in English | MEDLINE | ID: mdl-15048088

ABSTRACT

The transcription factors STAT5A and STAT5B (STAT: signal transducer and activator of transcription) play a major role in the signaling events elicited by a number of growth factor and cytokine receptors. In this work, we aimed to investigate the role of STAT5 in human precursor B cell survival by introducing dominant-negative (DN) forms of STAT5A or STAT5B in the 697 pre-B cell line. All clones expressing DN forms of either transcription factor exhibited a higher spontaneous apoptotic rate that was massively enhanced upon interleukin-7 (IL-7) stimulation. This was associated with caspase 8 cleavage, mitochondrial transmembrane potential disruption and caspase 3 activation. However, the DN forms of STAT5 did not alter the expression of Bcl-2, Bax, Bcl-x, Bim, A1 and Mcl1 proteins in IL-7-stimulated cells. The pancaspase inhibitor Z-Val-Ala-Asp-fluoromylmethyl ketone partially suppressed IL-7-mediated mitochondrial transmembrane potential disruption and cell death, suggesting that IL-7 induced the death of DN STAT5 expressing 697 cells through caspase-dependent and -independent mechanisms that both require mitochondrial activation.


Subject(s)
Apoptosis/immunology , B-Lymphocytes/immunology , Caspases/metabolism , DNA-Binding Proteins/genetics , Interleukin-7/pharmacology , Milk Proteins , Trans-Activators/genetics , Apoptosis/drug effects , B-Lymphocytes/cytology , B-Lymphocytes/drug effects , B-Lymphocytes/physiology , Caspase 3 , Cell Death/drug effects , Cell Line , Humans , Mitochondria/drug effects , Mitochondria/immunology , STAT5 Transcription Factor , Tumor Suppressor Proteins
9.
Br J Haematol ; 123(5): 933-41, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14632786

ABSTRACT

Glucorticoids reduce eosinophilia through a direct effect on eosinophils or indirectly on cells producing cytokines and chemokines. Conflicting data have been previously reported concerning glucocorticoid effects on eosinopoiesis. To elucidate this point, dexamethasone was added during eosinophil differentiation of CD34+ cells. Dexamethasone enhanced proliferation and differentiation through an early effect on immature cells. Dexamethasone inhibited apoptosis during early differentiation, whereas death of mature cells was increased. Signal transducer and activator of transcription 5 (STAT5) is a transcription factor involved in the proliferation, differentiation and survival of haematopoietic cells, which interacts with glucocorticoid receptor. Activation of STAT5 by interleukin-5 was investigated during eosinophil differentiation. Long isoforms of STAT5 were activated during the entire period in the culture as well as in blood eosinophils, while short isoforms were only activated during early differentiation. Short isoforms were less activated in the presence of dexamethasone. This suggests that dexamethasone could act on proliferation, differentiation and apoptosis during eosinophil differentiation through an association of STAT5 with the glucocorticoid receptor.


Subject(s)
DNA-Binding Proteins/metabolism , Dexamethasone/pharmacology , Eosinophils/cytology , Glucocorticoids/pharmacology , Leukopoiesis , Milk Proteins , Signal Transduction/drug effects , Trans-Activators/metabolism , Antigens, CD34 , Apoptosis/drug effects , Cell Differentiation/drug effects , Cells, Cultured , Eosinophils/immunology , Eosinophils/metabolism , Fetal Blood , Humans , Interleukin-5/pharmacology , Protein Isoforms/metabolism , STAT5 Transcription Factor , Stimulation, Chemical
10.
Eur J Immunol ; 33(5): 1372-81, 2003 May.
Article in English | MEDLINE | ID: mdl-12731064

ABSTRACT

We have previously shown that Fas-induced apoptosis is markedly enhanced by IL-7 in human pre-B but not pro-B cell lines. In addition, pre-B cell receptor (pre-BCR) ligation significantly potentiates the IL-7 effects on Fas-triggered pre-B cell death. We show herein that transforming growth factor (TGF)-beta 1 sharply reduces Fas-induced death rate of pre-B but not pro-B cells. TGF-beta 1 causes inhibition of Fas-mediated disruption of mitochondrial transmembrane potential and cleavage of caspase 8, Bid and caspase 3. Bcl2 expression is markedly increased in TGF-beta 1-treated pre-B cells, whereas cellular FLICE-like inhibitory protein long (c-FLIPL), Bcl-XL, Bax, and Bad expression remains unchanged. TGF-beta 1 causes a selective growth arrest of pre-B cells in G0/G1 phase of the cell cycle and induces a partial down-modulation of both Fas and pre-BCR expression. All TGF-beta 1-mediated effects, but Bcl2 up-regulation, can be reproduced by the LY294002 phosphatidylinositol 3-kinase (PI3K)/Akt inhibitor but not by inhibitors of the MAPK/ERK (MEK) and Janus kinase (Jak)/STAT pathways, which promote cell death. Akt phosphorylation is strongly inhibited by TGF-beta1 in pre-B but not pro-B cells and is not modified by Fas engagement. Altogether, our findings suggest that TGF-beta1 prevents Fas-induced apoptosis of pre-B lines by inhibiting PI3K pathway and by enhancing expression of Bcl2. They also suggest that the PI3K/Akt pathway is involved in the control of Fas and pre-BCR expression, a checkpoint in B cell development.


Subject(s)
Apoptosis/drug effects , B-Lymphocytes/physiology , Hematopoietic Stem Cells/physiology , Protein Serine-Threonine Kinases , Transforming Growth Factor beta/pharmacology , fas Receptor/physiology , B-Lymphocytes/drug effects , Cell Division/drug effects , Cell Line , Hematopoietic Stem Cells/drug effects , Humans , Mitochondria/physiology , Phosphoinositide-3 Kinase Inhibitors , Proto-Oncogene Proteins/antagonists & inhibitors , Proto-Oncogene Proteins c-akt , Proto-Oncogene Proteins c-bcl-2/analysis , Transforming Growth Factor beta1
11.
FEBS Lett ; 537(1-3): 111-6, 2003 Feb 27.
Article in English | MEDLINE | ID: mdl-12606041

ABSTRACT

Eosinophil-derived neurotoxin (EDN) is one of the four basic proteins stored in specific eosinophil granules. Here we demonstrate that EDN can also be detected at the surface of granulocytes. Reduction of EDN membrane expression after phosphatidylinositol-specific phospholipase C treatment suggests that a glycosylphosphatidylinositol (GPI) anchor is involved in the membrane association of EDN. The presence of a GPI anchor was confirmed by a lower expression of membrane EDN on granulocytes from patients with paroxysmal nocturnal hemoglobinuria which present cells lacking GPI anchor proteins. Furthermore, metabolic labeling with GPI anchor components supports biochemical evidence of GPI anchoring of EDN.


Subject(s)
Glycosylphosphatidylinositols/physiology , Granulocytes/drug effects , Ribonucleases/toxicity , Blood Donors , Cytoplasmic Granules/chemistry , Eosinophil-Derived Neurotoxin , Eosinophilia/blood , Eosinophils/chemistry , Flow Cytometry , Granulocytes/cytology , Granulocytes/pathology , Hemoglobinuria, Paroxysmal/blood , Humans , Leukocyte Count , Neutrophils/cytology , Neutrophils/drug effects , Neutrophils/pathology , Reference Values , Ribonucleases/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...